Marys Medicine

Microsoft word - mps_procedure_guidelines final 12.doc

Procedure Guidelines for Radionuclide Myocardial Perfusion
Imaging with Single-Photon Emission Computed
Adopted by the British Cardiac Society, the British Nuclear Cardiology Society,
and the British Nuclear Medicine Society
Writing Group: P Arumugam; M Harbinson, E Reyes, N Sabharwal, C Tonge, SR Underwood
Advisory Group: Andrew Kelion
Address for Correspondence:
Dr Parthiban Arumugam Consultant Nuclear Physician Nuclear Medicine Centre Manchester Royal Infirmary Manchester M13 9WL This document is an update of the 2004 procedure guidelines for myocardial perfusion scintigraphy. Some of the previous recommendations have been updated or replaced by evidence-based statements and new sections have been added.
Myocardial perfusion scintigraphy (MPS) uses an intravenously administered radiopharmaceutical to image myocardial viability and perfusion during stimulation of the perfusion system and at rest. The images are acquired using a gamma camera and tomographic imaging is preferred over planar imaging because of the three dimensional nature of the images and their superior contrast resolution. Comparison of the myocardial distribution of radiopharmaceutical after stress and at rest provides information on myocardial viability, inducible perfusion abnormalities and, when ECG-gated imaging is used, global and regional Clinical governance makes it mandatory for practice to be based upon evidence whenever possible. This is best achieved by expert analysis of the evidence and to this end the British Nuclear Cardiology Society (BNCS) in association with the British Cardiac Society (BCS) and the British Nuclear Medicine Society (BNMS) have developed procedure guidelines for emission tomographic myocardial perfusion imaging. The guidelines are intended to assist medical practitioners and other healthcare professionals in recommending, performing, interpreting and reporting single-photon emission computed tomography (SPECT) of myocardial perfusion. They do not cover the benefits or drawbacks of the technique in specific circumstances; neither do they address its cost effectiveness in clinical diagnosis and management nor its potential impact on clinical outcomes. Only brief comment is made on other nuclear techniques for assessing myocardial perfusion such as positron emission tomography (PET).
2. Methods of Guideline Development
The writing group was composed of clinicians and scientists from different specialities but all with sub-speciality expertise in nuclear cardiology. The advisory group consisted of nominated representatives of the BNCS, the BNMS and the guidelines committee of the BCS. Every effort was made to avoid conflict of interest from non-clinical relationships, and the final document was approved by the three societies. New references and supporting evidence were included and data summarised by each guideline developer with discrepancies reconciled by consensus. All recommendations are based on either evidence from clinical studies, previous published guidelines or expert consensus of the writing and advisory groups.
3. Indications for Myocardial Perfusion Scintigraphy
 To assess the presence, site and degree of coronary obstruction in patients with suspected coronary artery disease  To aid the management of patients with known coronary heart disease: to determine the likelihood of future coronary events, for instance after an acute coronary syndrome (ACS) or related to proposed non-cardiac surgery [1 2] to guide strategies of myocardial revascularisation by determining the haemodynamic significance of coronary lesions [3] to assess the adequacy of percutaneous and surgical revascularisation[4]  To assess myocardial viability and hibernation, particularly with reference to planned  Special indications are: to assess the haemodynamic significance of known or suspected anomalous coronary arteries and muscle bridging[6 7] to assess the haemodynamic significance of coronary aneurysms in Kawasaki's to assess risk in asymptomatic patients with chronic kidney disease[10] to assess the presence and extent of obstructive coronary artery disease in patients with arrhythmia. Although a common request, there are little data to support this indication.
4. Stressing the Myocardial Perfusion System
4.1. Dynamic exercise
Dynamic exercise is the stress technique of choice in the assessment of patients with suspected or known coronary artery disease provided that the patient is able to exercise to an acceptable workload. In particular, dynamic exercise is the ideal form of stress for patients with suspected or known anomalous coronary arteries, muscle bridging or microvascular disease. Exercise should be avoided in patients with left bundle branch block (LBBB) or paced rhythm on their resting ECG as it may result in perfusion abnormalities in the absence of coronary artery 4.1.2 Patient Preparation  Withdrawal of medications that may interfere with the physiological response to exercise should be considered. In general, for the performance of diagnostic studies, beta- blockers should be withdrawn for 48 hours or for the equivalent of five half-lives prior to the test unless medically contraindicated. The continuation of these agents may lead to underestimation of the extent of inducible perfusion abnormality.[12] Other anti-anginal medication, in particular calcium channel antagonists and nitrates, may be withheld for 24-48 hours prior to the stress test.
 Patients should also abstain from caffeine containing foods and from methylxanthine containing drugs (aminophylline, theophylline) for a minimum of 24 hours prior to the test.
This practice allows the use of vasodilator agents in cases where the exercise is terminated and pharmacological stress is undertaken (see section 4.2 below).
 Patients should be instructed to dress appropriately for exercise.
 Some authorities recommend that patients should fast for a minimum of 2 hours prior to the test. The advantage of this however is unproven.
 Exercise testing must be led by a suitably trained healthcare professional. In the absence of a national position statement for appropriate training, there must be a local statement of suitable training and experience. If the test is not being performed by a physician, a physician experienced in cardiovascular stress should be available with urgency appropriate to the situation as defined in local or national guidelines.[13 14]  The healthcare professional supervising the stress should be current in immediate life support (ILS) provided that there is rapid access to personnel trained in ALS and that appropriate assistance and emergency support is available.
Patients should be given an explanation of the purpose and conduct of the test, including information on potential side effects and complications. Consent is obtained verbally in most centres.
 Initial evaluation should include medical history (including symptoms, cardiovascular risk factors, medication and prior diagnostic and therapeutic procedures) and review of referral letter and other medical records if available. Physical examination may also be required, particularly if contraindications to dynamic exercise such as left ventricular outflow obstruction are suspected.
 Justification and authorization for performing the test should be confirmed before starting in accordance with the Ionising Radiation (Medical Exposure) Regulations 2000[15] and any local procedures that ensure compliance.
 Dynamic exercise can be performed using a treadmill or a bicycle ergometer. Most treadmill protocols for exercise testing include an initial period of warm-up, progressive uninterrupted exercise with increasing workloads in each level until an end point is achieved, and a recovery period. The preferred method is the Bruce protocol.[16] Bicycle ergometer protocols generally involve an initial low workload of 25 watts, followed by increases of 25 watts every 2 or 3 minutes until end points are achieved.[17]  Regardless of the exercise protocol used, an intravenous line should be secured and flushed with 5-10 ml of sodium chloride 0.9% injection to ensure patency before starting  Haemodynamic parameters (heart rate and blood pressure) and electrocardiogram (ECG) should be monitored at rest and throughout the test and recorded at each stage.
Monitoring should continue for 5 minutes after exercise or until changes stabilize, and haemodynamic parameters and ECG are close to baseline. Monitoring with a 12-lead ECG is required for the detection of ST segment and T wave changes and for the diagnosis of arrhythmias.
 Exercise duration, symptoms, reason for stopping and dynamic ECG changes should be 4.1.4 End Points and Radiopharmaceutical Injection Exercise should be symptom-limited with patients achieving at least 85% of the age- and gender-maximal predicted heart rate. The radiopharmaceutical should be injected close to peak exercise. The patient should continue exercising if feasible for one minute after thallium-201 injection or for two minutes after technetium-99m perfusion tracer injection.
Exercise testing should be stopped if there is:  ST segment elevation >0.1 mV in leads without Q waves  a drop in SBP >20 mmHg below baseline or of more than 20% from a previous stage despite an increase in workload, if this is considered to be related to myocardial  serious arrhythmias (e.g. VF, VT, frequent and symptomatic VPBs, multifocal VPBs, AF, SVT, second or third degree atrioventricular block and symptomatic bradycardia)  severe angina  physical signs of peripheral hypoperfusion such as cyanosis or pallor  central nervous system symptoms such as ataxia, dizziness or near syncope Horizontal or downsloping ST depression below baseline of ≥0.2 mV 80 ms after the J point is not necessarily an indication for termination of exercise unless it is associated with severe symptoms.
4.2 Pharmacological stress
Pharmacological stress is an alternative to dynamic exercise, provided that exercise tolerance, symptoms and ECG changes during dynamic exercise are not required (table 1). It has the advantages of speed, reliability and reproducibility, but the disadvantages that it is not possible to monitor the adequacy of stress and it is not equivalent to physiological stress experienced by the patient in everyday life. Pharmacological stress with vasodilators is the procedure of choice for patients unable to exercise adequately [18 19] and for those with LBBB or paced rhythm.[11] Patient Preparation Some authorities recommend that patients should fast for a minimum of 2 hours prior to stress testing. The advantage of this however is unproven.
Patients stressed with the vasodilators adenosine, regadenoson or dipyridamole must avoid consumption of any products containing methylxanthines including caffeinated foods and drinks (coffee, tea, chocolate), caffeine-containing medications, aminophylline and theophylline for a minimum of 24 hours prior to the test.[20 21] Caffeine ingestion may attenuate the normal vasodilator response to adenosine,[22]dipyridamole[23] and regadenoson.[24] Attenuation of adenosine-induced perfusion abnormality by caffeine can be overcome by increasing the adenosine dose (see section 4.3 below). Dipyridamole should be withheld for at least 24 hours prior to adenosine or 48 hours before Regadenoson administration. If feasible, beta blocker medication should be withdrawn 48 hours, or for the equivalent of five half-lives, prior to the test.
The continuation of beta-blockers may lead to underestimation of the extent and depth of inducible perfusion abnormality.[25] Other antianginal medication, in particular calcium channel antagonists and nitrates should be discontinued prior to the test if possible (see section 4.1.2).
A detailed explanation of the procedure should be given, outlining possible side effects and complications. Consent is obtained verbally in most centres.
Dobutamine stress Patients should stop beta-blockers for 48 hours, or for the equivalent of five half-lives, prior to the test. The continuation of beta-blockers may lead to underestimation of the magnitude of inducible perfusion abnormality.[26] A detailed explanation of the procedure should be given, outlining possible side effects and complications. Consent is obtained verbally in most centres.
The stress must be led by a suitably trained healthcare professional as for dynamic exercise (see paragraph 4.1.3). Initial evaluation of the patient's medical history, examination if appropriate, and justification and authorization for performing the test are mandatory.
For administration of adenosine, an intravenous line is required and a 3-way connector should be used to allow tracer injection without interruption of the adenosine infusion. However, the tracer injection should be given over 10 to 20 seconds to avoid a sudden bolus of adenosine.
The adenosine is infused at 140 mcg/kg/minute for 6 minutes using an infusion or syringe pump.
This may be coupled with submaximal dynamic exercise when tolerated to reduce the frequency and severity of adverse effects associated with vasodilator infusion.[27] If this is the case a bicycle ergometer may be preferable to a treadmill because intravenous infusions are easily managed when the patient is relatively steady. Heart rate, blood pressure and ECG should be measured and recorded at baseline and every 2 minutes during the infusion. The tracer is injected between the third and fourth minutes of the adenosine infusion or sooner if symptoms or other complications require. Tracer injection as early as 2 minutes after the start of the infusion is probably effective. Symptoms during the test should be recorded. In patients with well- controlled or mild asthma or chronic obstructive pulmonary disease (COPD), adenosine can be given as a titrated protocol starting at a low dose of 70 or 100 mcg/kg/min for a minute and increasing if tolerated up to 140 mcg/kg/min with tracer injection two minutes after the maximal dose of 140 mcg/kg/min. Patients who are already on a beta-2 adrenergic agonist such as salbutamol can be given two puffs of the inhaler prior to starting the adenosine infusion.[28 29] Regadenoson is administered as a single dose of 400 mcg in 5 ml. No adjustment for patient weight, renal or hepatic function is needed. Regadenoson is given intravenously as a 10-second injection followed immediately by a 10-ml saline flush with tracer injection 10 to 20 seconds after the saline injection. Regadenoson can be combined with submaximal exercise when tolerated.
Regadenoson has also been used during dynamic exercise when maximal exercise is not achieved but there is little evidence for the effectiveness and safety of this approach.[30] Heart rate, blood pressure and ECG should be recorded at baseline and every 2 minutes until stress- induced haemodynamic changes are improving and the patient regains baseline status.
Symptoms during the test should be recorded. Regadenoson is well-tolerated and most side effects are mild and short-lasting but some symptoms may last up to 30 minutes.[31 32] Aminophylline (50 to 250 mg) may be administered as a low intravenous injection of 50-100 mg over 30-60 seconds to counteract persistent or intolerable symptoms. Patients with moderate to severe COPD as well as patients with mild to moderate asthma tolerate regadenoson well and hence this agent is not contraindicated in patients with obstructive airway disease but it should be administered with caution.[33 34] Intravenous dipyridamole is infused at a rate of 140 mcg/kg/minute for 4 minutes. The infusion can be given manually with care and it can be coupled with submaximal dynamic exercise when tolerated. Heart rate, blood pressure and ECG should be measured and recorded at baseline and every 2 minutes during the infusion until stress-induced haemodynamic changes are improving and the patient regains baseline status. The radiopharmaceutical should be injected 4 minutes after completion of the infusion. Symptoms during the test should be recorded.
Dipyridamole causes adverse effects that are similar to those of adenosine, although they are generally more prolonged.[35 36] Intravenous aminophylline (75-250 mg) may be required to reverse these although its half-life is shorter than that of dipyridamole (tables 2 and 3).[35 37] Dobutamine infusion is commonly used when dynamic exercise is not feasible and there are contraindications to vasodilator stress. It is administered as an intravenous infusion using an infusion or syringe pump in 3-5 minute stages at incremental doses of 5-10 mcg/kg/minute up to a maximum of 40 mcg/kg/minute.[38 39] Heart rate and blood pressure should be recorded at the end of each stage and the ECG should be monitored continuously. Side effects may occur during infusion in up to 75% of patients (tables 2 and 3). The radiopharmaceutical should be injected when ≥85% of the age- and gender-maximal predicted heart rate is reached or at 1 minute into the highest dobutamine dose. The dobutamine infusion should be continued for one minute after injection of thallium-201 or one to two minutes after injection of technetium-99m labelled tracers. Additional atropine at doses of 0.3 -0.6 mg up to 1-2 mg may be given to patients who do not achieve target heart rate with dobutamine infusion alone. Dobutamine infusion should be discontinued for the same reasons as exercise testing (see paragraph 4.1.4).
The presence of a healthcare professional who is current in immediate life support is required for the duration of all stress procedures. Personnel trained in ALS should be rapidly available.
Emergency equipment, medications and support personnel should also be available.
Absolute contraindications to dynamic exercise The following are generally considered to be absolute contraindications to exercise stress, though under some circumstances exercise may be clinically appropriate under experienced medical supervision:  ST-segment elevation myocardial infarction within the previous 4 days  non-ST-segment elevation acute coronary syndrome. Once stabilised, exercise stress can be considered 24 to 72 hours after chest pain depending upon clinically assessed  left main coronary artery stenosis that is likely to be haemodynamically significant  left ventricular failure with symptoms at rest  recent history of life-threatening arrhythmias  severe symptomatic dynamic or fixed left ventricular outflow tract obstruction (aortic stenosis and obstructive hypertrophic cardiomyopathy)  severe or malignant systemic hypertension  recent pulmonary embolism or infarction  thrombophlebitis or active deep vein thrombosis  active endocarditis, myocarditis or pericarditis Relative contraindications to dynamic exercise These are not strictly contraindications to dynamic exercise but they can compromise the specificity of the test:  left bundle branch block (LBBB) and ventricular paced rhythms, because dynamic exercise leads to perfusion abnormalities of the septum and adjacent walls in the absence of obstructive coronary disease  inability or poor motivation to perform dynamic exercise  recent exercise ECG with inadequate exercise Absolute contraindications to vasodilator stress  Unstable acute coronary syndrome. Adenosine stress can be performed early (24-48 hours) after an uncomplicated acute infarction  suspected or known severe bronchospasm, although regadenoson can be used in selected patients  second and third degree atrioventricular block in the absence of a functioning pacemaker  sick sinus syndrome in the absence of a functioning pacemaker  hypotension (SBP <90 mmHg)  xanthines (caffeine, aminophylline or theophylline) intake in the last 24 hours. Adenosine dose can be increased up a maximum of 210 mcg/kg/min if tolerated in patients who have consumed caffeine within 12 hours prior to the test.[41] Relative contraindications to vasodilator stress  bradycardia of less than 40 beats per minute. Initial dynamic exercise normally increases the rate sufficiently to start the infusion.
 dipyridamole medication taken in the last 24 hours. Initial low dose adenosine infusion with subsequent increase if tolerated is used in some centres but there is no published evidence to support this practice. Anecdotal experience suggests that IV dipyridamole can be administered safely in these circumstances but there is no evidence to support this practice.
 Recent cerebral ischaemia or infarction Absolute contraindications to dobutamine stress  as for dynamic exercise above  known hypokalaemia [42] Relative contraindications to dobutamine stress  LBBB and paced rhythm for the same reason as for dynamic exercise For SPECT imaging, thallium-201 and two technetium-99m labelled radiopharmaceuticals (sestamibi and tetrofosmin) are available commercially. For PET imaging, positron emitting radiopharmaceuticals Oxygen-15 water and Nitrogen-11 ammonia are also used, but because of their short half-life require an on-site cyclotron. Myocardial perfusion PET using Rubidium-82 has been shown to provide advantages in terms of more accurate attenuation correction and improved diagnostic accuracy, but is not widely available as yet.
It is important to check regarding pregnancy and breast feeding. For women of child bearing age national guidelines should be followed.[43] Pregnant women in general should not undergo tests which results in high radiation exposure to the foetus due to a small increase in risk of cancer. However the exposure from most of the current diagnostic procedures is less than 1 milligray and the additional risk of cancer is 1 in 10,000 compared to a natural risk of 1 in 500.[43] It is preferable to perform imaging in women of childbearing age, if clinically appropriate, within the first 10 days of menstrual cycle.[43] Breast feeding has been noted to cause intense breast uptake of thallium 201, Tc-99mm sestamibi and Tc-99m tetrofosmin leading to uninterpretable studies.[43] The duration of increased uptake following cessation of breast-feeding is unknown. For this reason it is recommended that myocardial perfusion studies should not be performed during breast feeding or for several months post cessation.[44] Thallium-201 is initially distributed after intravenous injection to the myocardium according to myocardial viability and perfusion. Because it is a potassium analogue, thallium-201 uptake reflects myocardial blood flow more accurately than any of the other SPECT tracers. It redistributes from this distribution over several hours, thus allowing redistribution images to be acquired that are independent of perfusion and reflect viability alone. However its physical characteristics of low energy (80KeV) and relatively long half-life (73hrs) lead to low count images and increased attenuation artefacts as compared with technetium radiopharmaceuticals and higher radiation dose. Gated images are possible, but the low count statistics may be a cause for concern. For these reasons thallium has mainly been superseded by technetium radiopharmaceuticals except for viability studies.
Allowable activity The maximum usual dose is 80 MBq for stress and redistribution imaging. An additional 40 MBq can be given at rest for reinjection imaging if redistribution is thought to be incomplete at the time of redistribution imaging or if redistribution is predicted to be slow.[45 46] Such reinjection doses are not normally approved as a routine by the United Kingdom Department of Health's Administration of Radioactive Substances Advisory Committee (ARSAC)[47] and must be given at the discretion of the practitioner in individual cases. Higher doses can be considered on an individual basis in obese patients.
Thallium-201 should be administered through a secure intravenous line in accordance with local radiation protection practices. If it is given through the side arm of a three-way tap through which adenosine or dobutamine are running, then it should be given over 15- 30 seconds to avoid a bolus of the pharmacological stressor being pushed ahead of the thallium. Otherwise it can be given as a bolus injection. The thallium syringe can be flushed with three or four 0.5ml aliquots of either saline or the stressor solution to ensure that the full dose is given.
If a resting injection is given, for instance in a patient with a severe defect of uptake in the stress images, sublingual nitroglycerine (400-800µg) can be administered at least 5 minutes beforehand in order to reduce resting hypoperfusion and to increase the correspondence of the resting images with myocardial viability. Other nitrates such as buccal isosorbide dinitrate may also be used and these should be given in the supine position to avoid symptomatic hypotension.
Imaging Protocols  Different imaging protocols can be followed, depending on clinical indication(s) and local practices: stress-redistribution, stress-reinjection, stress-redistribution-reinjection, stress- reinjection-delayed 24 hour imaging.
 Stress imaging should begin within 5 minutes of stress injection and should be completed within 30 minutes of injection.
 Redistribution imaging should be performed 3-4 hours after the stress injection.
 In patients with severe perfusion defects in the stress images or if redistribution is thought to be incomplete at the time of redistribution imaging, a resting injection can be given (ideally after sublingual nitrates) with reinjection imaging after a further 60 minutes of redistribution.[48] This protocol is normally sufficient for the assessment of myocardial  Imaging can also be performed 24 hours after injection using a longer acquisition time for the assessment of myocardial viability.
5.2 Technetium-99m sestamibi and tetrofosmin
After intravenous injection these technetium-99m-labeled radiopharmaceuticals are distributed within the myocardium according to myocardial viability and perfusion. Unlike thallium-201 they have minimal redistribution and so separate injections are required for stress and rest studies.
The higher energy of technetium-99m generally leads to better quality images (because of less attenuation and scatter) and the better count statistics permits ECG-gating, which gives additional functional information. The radiation dose to the patient is considerably less than for thallium-201. However, their uptake as a function of myocardial perfusion is less avid than thallium-201 and so defects may be less profound.
Allowable activity The maximum usual dose for tomography is a total of 1600 MBq for a one-day stress/rest protocol (divided as 400 MBq and 1200 MBq),or 800MBq on each day of a two-day protocol.[47] Two-day protocols are recommended on the grounds of superior image quality but these may not be practicable. If a one-day protocol is performed, a count density of 1:3 or 4 between the two studies is recommended. Higher doses can be considered on an individual basis by the practitioner, for instance in obese patients. Administered activity may be increased on a graded basis either based on body weight or body mass index with an aim to achieve a constant count density (counts/pixel) independent of body habitus. This should be implemented only following specific approval from ARSAC.[47]  The radiopharmaceutical should be administered through a secure intravenous line in accordance with local radiation protection practices. The same considerations as described above for thallium-201 apply.
 As with thallium-201, resting injections can be given under nitrate cover and this is important when assessing myocardial viability because the absence of redistribution means that viability is underestimated in areas with reduced resting perfusion.[49 50] Imaging Protocols  Different imaging protocols can be followed, depending on clinical indication(s) and local practices: one-day stress-rest, one-day rest-stress, two-day (especially for obese patients). The two-day protocol is recommended on the grounds of image quality, but it may be less convenient for the patient. The one-day protocols are acceptable alternatives provided that it is recognised that residual activity from the first injection contaminates the second image.
If a one-day protocol is performed, a rest-first study has advantages including better contrast between normal and ischaemic segments and lesser time interval between the two studies. However, in patients with low pre-test likelihood of obstructive coronary disease, one might wish to consider a stress- first study, especially with ECG gating and attenuation correction to obviate the need for a rest study.
 Imaging should begin 30-60 minutes after injection to allow for hepato-biliary clearance with longer delays required for resting images and for stress with vasodilators alone because of the higher liver uptake.
 A fatty meal can be given between injection and imaging to aid clearance of tracer from the liver and gall bladder. The value of this manoeuvre is uncertain and it may be counter-productive if there is retrograde passage of tracer from duodenum to stomach or if the tracer reaches the transverse colon.[51 52] A fizzy drink or a water-based beverage immediately before imaging may also reduce interference from gut activity.[53] 6. Image Acquisition
Image acquisition should be performed using a gamma camera that meets accepted standards of quality control (QC).[54 55] For SPECT/CT systems quality control of the CT component is also important. Daily QC of the CT must include the manufacturer prescribed x-ray tube warm- up procedure and automatic monitoring (usually at various tube voltage and current settings) of the x-ray tube output and detector response. Additional evaluation of tomographic uniformity, CT number values (Hounsfield units) and image noise should be performed daily to weekly (modern scanners may include this as part of their required daily CT QC).[56] There have been advances in gamma camera technology recently, including solid state technology, innovative collimator designs, and the incorporation of resolution recovery software.
The combination of these features can offer greatly improved detector sensitivity together with improved spatial and energy resolution over that of conventional gamma cameras. Solid state dedicated cardiac cameras are already commercially available. This technology is rapidly evolving so there are as yet no recommendations for quality assurance of these systems or for the imaging protocols to be used with them. Centres using these systems must ensure suitable quality assurance tests are devised and that imaging protocols have been validated with phantoms before use.
6.1 Patient positioning
For conventional gamma cameras the patient is usually supine with one or both arms above the head and supported in a comfortable position. It is desirable that the left arm should lie outside the imaging arc of the camera. Patient comfort is essential to minimise motion. A knee support may be useful to minimize back discomfort. It is essential that patient positioning is reproducible between stress and rest imaging. Prone imaging has been used in some centres to reduce the incidence of inferior attenuation artefact[57] but it can produce anterior artefacts and it is not recommended in isolation.
Female patients should be imaged without underclothes. A chest band may be used to minimise breast attenuation and to ensure reproducible positioning during later image acquisition. This can however increase attenuation depending upon how the band is applied and careful attention to technique is required when the breasts are strapped. Chest bands can also be used in males to reduce motion.
6.2 Acquisition parameters
These recommendations apply to conventional gamma cameras and are not applicable to newer technologies such as those mentioned above, for which the manufacturer's recommendations should be followed.
 Dual head tomographic imaging is commonly performed over a 180o rotation from RAO 45°to LPO 45°. A circular or non-circular orbit can be used according to preference.
 Low-energy general purpose collimation should be used for thallium-201. If resolution recovery software is available the use of low energy general purpose collimation for technetium-99m tracers should also be considered in order to reduce either the acquisition time or the administered dose. For gamma cameras without availability of resolution recovery software high-resolution collimation should be used for technetium-  A 15%- 20% energy window at 72 and 167 keV for thallium-201 and 140 keV for technetium-99m-labeled radiopharmaceuticals should be selected.
 The acquired pixel size should be in the region of 6mm.[59] A zoomed acquisition can be used depending upon camera dimensions but care must be used that the patient lies within the field of view in all projections.
 A step-and-shoot acquisition with 32 or 64 stops separated by 3-6o or a continuous acquisition can be used. The duration of acquisition at each stop depends partly on the equipment, protocol, dose of radiopharmaceutical, patient size and reconstruction algorithm. Total acquisition times of longer than 20-30 minutes can be counterproductive as they increase the likelihood of patient motion.[59]  ECG-gating should be performed, particularly with technetium-99m-labeled radiopharmaceuticals. Eight frames per cardiac cycle is commonly used, but sixteen frames per cardiac cycle provides more accurate measurement of left ventricular ejection fraction or parameters of diastolic function.[60]  The decision whether to perform ECG gating in patients with significant variation in R-R interval (arrhythmias) should be made on an individual patient basis. Newer gamma cameras with ‘9th bin' capability allow gated data acquisition with a narrow window (e.g.
20%) even in the presence of arrhythmias without compromising the static perfusion data. If this facility is not available, then using a widest possible R-R interval is recommended. When acquiring gated data with a wide window, frequency of ectopic beats should be monitored and if there is more than 1 ectopic per 6 normal beats, the gated acquisition should be abandoned.
 Planar images can be acquired prior to the tomographic acquisition to determine the lung-to-heart ratio although qualitative or quantitative assessment of lung to heart ratio can be made from the tomographic acquisition.[58]  The planar projection images should be reviewed immediately after acquisition to check for unacceptable motion, low count density, interference from high gut activity or other source of artefact such as foreign objects or motion of the heart outside the field of view in some projections.[58] 7. Attenuation Correction: Methods and Acquisition
Non-homogeneous photon attenuation is a cause of artefact limiting diagnostic accuracy. A number of techniques have been developed for correcting for attenuation. Many of these incorporate additional corrections for scatter and for depth-dependent resolution recovery.
Attenuation correction provides a modest increase in diagnostic accuracy.[61 62] However care should be taken with their use as new forms of artefact can be introduced by overcorrection or by mis-registration between the CT images and the reconstructed slices. Attenuation correction of SPECT images may be performed either using a radionuclide line source (e.g.gadolinium- 153) or more commonly now by using a CT detector integrated into the gamma camera gantry.
However it may itself introduce artefacts of its own. Misalignment between emission and transmission data can risk incomplete correction and create artificial perfusion defects. Mis- registration of just 1 pixel can cause a diagnostically significant artefact.
The registration between emission and transmission images must be assessed carefully and registration correction performed when necessary. Attenuation correction should be incorporated with scatter correction in an iterative reconstruction and should not be applied alone. There is evidence that when applied correctly attenuation correction can increase diagnostic 8. Image Processing
Resolution recovery software is now available from many manufacturers. It can be used to achieve comparable or better image quality with lower count density than standard iterative techniques. Parameters need to be optimised to suit local preferences and equipment. Its use is encouraged if available.
 When resolution recovery software is not available iterative reconstruction should be used rather than filtered background projection if attenuation correction has been performed and it can also be used without attenuation correction.
 When neither resolution recovery nor iterative reconstruction is available filtered back projection using Butterworth and Hanning filters is still an acceptable method of reconstruction. Cut-off frequencies should be chosen according to the manufacturer's recommendations. These should be the same for each patient and should not be altered to compensate for low-count images in order to maintain consistency of appearance.[59] The long axis of the left ventricle is defined from the apex to the centre of the mitral valve and definition of the axis can be manual or automatic. Automatic definitions should be checked and adjusted if necessary. The definition should be consistent in both stress and rest studies bearing in mind that the orientation of the ventricle may change slightly between acquisitions.
The transverse tomograms are reoriented into three sets of oblique tomograms: (1) short axis (perpendicular to the long axis of the left ventricle), (2) vertical long axis (parallel to the long axis of the left ventricle and to the septum), and (3) horizontal long axis (parallel to the long axis of the left ventricle and perpendicular to the septum).
8.3 Image evaluation
The planar projection images and the reconstructed tomograms should be inspected immediately after acquisition by an operator or practitioner in order to identify technical problems that might require repeat acquisition. These might include:  injection site or external objects passing across the heart  patient motion; significant motion may not be appropriately corrected by motion correction software and hence images should be re-acquired whenever possible;  inaccurate ECG-gating; gated parameters should not be reported if this is the case and if severe enough and there is no provision of an ‘extra bin', a non-gated study should be re-  interference from high gut activity close to the heart; this may cause artefactual reduction in counts in adjacent regions of the myocardium or may obscure a real perfusion abnormality; image re-acquisition should be considered if severe;  problems related to the detector(s), such as drift in energy window and artefact(s) generated by transition between the two detectors;  inappropriate collimation or energy windows.
For attenuation corrected images the registration of the reconstructed slices with the CT images should be checked and the images re-registered or repeated if mis-registration is severe.
8.4 Image display
Stress and rest images should be appropriately aligned and presented in a format that allows ready comparison of corresponding tomograms, such as interactive displays that triangulate the three planes or display the full set of tomograms.
The use of a continuous colour scale is recommended when reviewing tomograms, as it provides semi-quantitative information on count distribution throughout the myocardium, and it also improves image interpretation for non-experts.[64] Each tomographic acquisition should be displayed with the top of the colour scale at the maximum within the myocardium for each set.
Displays with the top of the colour scale at the maximum of each individual tomogram and those that use the same maximum for stress and rest images should not be used. Care should be taken if the maximum lies outside the myocardium and manual adjustment or masking of extracardiac activity may be required. The bottom end of the colour scale should be set to zero and background subtraction should be avoided. Neighbouring pairs of tomograms can be summed for display according to local preference.
8.5 Attenuation correction: Interpretation
Corrected images should not be used without review alongside the uncorrected images. The reader should familiarise themselves with the changes in image appearance caused by attenuation correction such as reduced apical counts or increased inferior counts.
Newer SPECT/CT AC systems are becoming ubiquitous. While most departments use low dose/resolution CT for attenuation correction, if the CT component is considered to be of diagnostic quality, it is good clinical practice to review the CT images obtained for abnormalities.
There should be a local policy for the reporting of the low dose CT images obtained for AC.
When non-cardiac abnormalities are identified, this should be communicated to the referring clinician with an appropriate recommendation for further investigation. This may require joint reporting sessions with CT accredited physicians.
9.1 Review of clinical details
It can be helpful initially to review the images without reference to clinical information in order to decide upon major features, and then to modify the opinion and decide upon minor features if necessary after review of the clinical information. Attention should be paid to the patient's height, weight and chest size as these may influence the degree of attenuation and quality of the study, and also to what findings would be expected from the clinical information. Unexpected findings are more likely to be artefactual.
The adequacy of stress should be noted as well as the exercise time, symptoms, haemodynamic observations and ECG changes. It is helpful to report together with the individuals who took the history, stressed the patient and/or acquired the images since symptoms and other observations during stress can influence reporting.
9.2 Review of projection data
Before interpreting the tomograms, the stress and rest projection data should be inspected alongside each other in a synchronised cine display using a linear grey scale (table 4):  to check that the heart is in the field of view throughout the acquisition  to look for sources of artefact including patient motion, upward creep, attenuation by soft tissue and external objects, hot activity adjacent to the heart that might obscure myocardial activity or cause reconstruction artefact, and low count artefact[65]  to look for evidence of left ventricular dilatation (either permanent or transient) or right ventricular hypertrophy and/or dilatation  to check whether there is increased lung uptake of tracer particularly thallium-201 (>50% of maximum myocardial uptake),[66]significant tracer uptake outside the heart or extravasated radiopharmaceutical at the site of venepuncture.
 to assess the pattern of myocardial uptake, although this is more clearly seen in the 9.3 Review of tomograms
Reconstructed tomograms should be viewed on a computer screen for reporting.
Reporting from film or paper reproductions should be avoided.
 The three tomographic planes should be displayed: vertical long axis, horizontal long axis and short axis.
 A continuous colour scale should be used because it provides the best inter-observer  For ECG-gated and ungated studies, if automatic edge detection is used, the computer- derived edges should be inspected to ensure that they have been correctly defined.
Incorrectly defined endocardial and epicardial borders will lead to wrong volume and ejection fraction calculations, and to incorrect polar displays and quantification.
Left Ventricular Size and Right Ventricular Uptake and Size Assessment of the tomographic images should begin with a qualitative assessment of the left ventricular cavity size in both sets of images. Dilatation that is worse in the stress images than at rest may indicate ischaemia-induced dilatation.[66] This is seen less commonly with technetium-99m tracers because of the delayed imaging. Care should be taken that areas of reduced uptake in the stress images do not simulate dilatation. Tracer uptake in the right ventricle should also be noted. Significant right ventricular tracer uptake (>50% of maximum left ventricular uptake) indicates right ventricular hypertrophy, and the right ventricle may also be Perfusion Defect Localisation, Extent and Severity Tracer uptake should be evaluated visually in all areas of the left ventricular myocardium.
Segmental analysis can be performed using a number of models of the left ventricular myocardium, and a 17 segment model is recommended by several American societies.[68] Tracer uptake can be classified semi-quantitatively as normal (100-70% maximal uptake), mildly reduced (69-50% maximal uptake), moderately reduced (49-30% maximal uptake), severely reduced (29-10% maximal uptake), and absent (9-0% maximal uptake). These figures are approximate and allowance should be made for normal variation and for artefact. Thus, the inferior wall may be judged to have normal uptake at much lower values if attenuation artefact is considered to be present.[69] Review of ECG-gated Tomograms  The beat-length histogram, if available, and the time-volume curve should be inspected to ensure that gating was appropriate. Cine inspection of the gated tomograms may also give clues of inadequate gating, such as inappropriate positioning of diastole or reduced counts in some frames.
 The computer-derived endocardial and epicardial edges should be checked to ensure that they have been appropriately selected.
 Wall motion is best evaluated in linear grey scale without computer-derived edges, and can be classified as normal, hypokinetic, akinetic or dyskinetic (paradoxical).[69]  Computer generated contours can be helpful but these should not be used as the sole determinant of motion.
 Wall thickening is best evaluated in a continuous colour scale without computer-derived edges, and is related to the increase in counts between diastole and systole. Computer generated contours can be helpful but these should not be used as the sole determinant of thickening. Thickening can be classified as normal, reduced or absent.[69]  Left ventricular end-diastolic volume, end-systolic volume, stroke volume and ejection fraction may be calculated automatically, although the values obtained should be checked against initial qualitative assessment. Caution should be exercised in reporting apparently spurious values of these parameters. For instance, volumes are often too low and ejection fraction too high in small ventricles.[60] For routine clinical reporting, formal quantitative analysis may not be necessary. However, it can be helpful to supplement semi-quantitative visual analysis with quantitative analysis of the polar display, particularly to measure the extent and depth of abnormalities.[70] The patient's polar map is compared with a normal database, which should be gender- and radionuclide-specific and may also be institute-specific. An alternative to the polar display is the display of circumferential count profiles but this is less common. Any form of quantification should be validated in published studies and the methodology used should be fully described and should be understood by those who use the technique. Quantitative results must not be reported in isolation and without expert review of the images from which the results are derived.
9.5 Integration of findings
The tomographic findings should be integrated to reach a final interpretation:  An improvement in relative tracer uptake from stress to rest ("inducible perfusion abnormality") often indicates the presence of inducible ischaemia. An improvement in tracer uptake of one category indicates mild inducible ischaemia, of two categories indicates moderate inducible ischaemia, and of more than two categories indicates severe inducible ischaemia.[69]  A reduction in tracer uptake that does not change from stress to rest ("fixed perfusion abnormality") normally indicates myocardial infarction, and the degree of reduction indicates the transmural extent of infarction from mild partial thickness infarction to full thickness infarction. However, when reporting partial-thickness infarction it should be borne in mind that the relationship between counts and transmurality of infarction is not linear because of partial volume effect in thinned myocardium.
 Differentiation between true abnormality of tracer uptake and artefact requires experience. Features in favour of attenuation artefact are visualisation of the attenuating structure in the projection images, the fixed nature of the defect especially if moving normally on ECG-gated images, an expected site (e.g. inferior wall or anterior wall in women), of limited extent, smooth edges, poor correspondence with a coronary territory, or an unexpected finding. None of these features however is universally reliable.
Features indicating reconstruction artefact are a limited mild-to-moderate fixed defect at the apex ("apical thinning") or intense liver or gall bladder activity that passes behind the inferior wall in the projection images.[65]  A deterioration in tracer uptake from stress to rest ("rapid tracer washout" or "reverse redistribution") is often artefactual but it may suggest partial thickness infarction with a patent artery.[71 72] The patient's personal details (name, age, gender and address) should be included at the start of the report. Any hospital/clinic identification number and source of referral should also be included (table 5).
The imaging protocol should be specified, including the radiopharmaceutical used, imaging technique, sequence and date of study.
Indication(s) for study The clinical indication(s) for the study should be stated, including relevant clinical history. This supports justification of the study, summarises clinical information that may have been gleaned from a number of sources and focuses the final conclusion.
The stress technique used should be described briefly, including any symptoms, haemodynamic changes and details of ECG changes during or after stress if relevant.
The appearance of the stress, rest and gated images should be described succinctly, including a statement on overall study quality if appropriate. Common practice is to report the defect(s) in the stress tomograms in decreasing order of severity, and then to state how each defect changes in the rest tomograms in the same order. At this stage tracer uptake is being described. Clinical deductions such as the state of myocardial viability and perfusion can be reserved for the conclusion (see below).
 The findings should be integrated to reach a final interpretation. Specifically, the report should comment on the presence (if any) of inducible perfusion abnormality, infarction and significant artefact. If there is an abnormality, its location (in terms of segments affected), extent (in terms of number of segments affected) and severity should be stated. Non-cardiac abnormalities, especially those derived from CT based AC systems should be interpreted.
 Other abnormalities to mention if present are 1) ischaemic ECG changes, hypotension (SBP<90mmHg) or blunted heart rate response during exercise or pharmacological stress, especially in the absence of perfusion abnormality. Such responses are associated with significant multivessel or left main stem disease and poor prognosis;[73 74] 2) left ventricular dilatation (persistent or transient); 3) increased lung uptake of tracer;4) right ventricular tracer uptake suggesting hypertrophy (with or without right ventricular dilatation); and 5) significant non-cardiopulmonary tracer uptake.
If the study is normal, this should be stated specifically bearing in mind that homogeneous myocardial perfusion during stress does not exclude non-obstructive coronary disease.
A statement on likelihood of future coronary events should be made if clinically relevant.
This is deduced from the presence, extent and depth of inducible perfusion abnormalities, the left ventricular ejection fraction if known, and other markers of prognosis such as transient dilatation and lung uptake. If no inducible perfusion abnormalities are present then the ejection fraction is the main determinant of prognosis.
This statement may be made in semi-quantitative terms (e.g. "the likelihood of future coronary events is in the region of 5-10% per year") since qualitative terms ("high", "intermediate", "low") are not uniformly interpreted.[75]  If correlation with coronary anatomy or assessment of myocardial viability or hibernation is relevant, these should be commented on bearing in mind the normal variation of coronary anatomy.
 Finally, it should be ensured that the conclusion answers the clinical question that prompted the referral if possible, and if not it may be relevant to make recommendations for further investigation or management.
10. Factors Affecting the Quality of Studies
Inadequate stress reduces the sensitivity for detecting coronary artery disease (table 6).[18] Tracer dosage and delivery
Inadequate delivery of radiopharmaceutical degrades image quality and may decrease the diagnostic accuracy of the technique. This may occur if the wrong dose of tracer for patient weight/size is administered or if the injection is inadequately flushed or extravasated.
Inappropriately timed tracer delivery (i.e. not coinciding with peak stress) may reduce the sensitivity of the technique.
Image reconstruction and processing
Inappropriate filtering during tomographic reconstruction may degrade image quality, while inappropriate use of colour or grey-scale windows may lead to diagnostic inaccuracies. For quantitative analysis of regional myocardial and lung activity, care should be taken that regions of interest do not include activity from adjacent structures.[76] 11. Audit and consensus reporting
All aspects of Nuclear Cardiology procedures should be regularly evaluated for quality. For example, there may be opportunity to take part in UK regional audits such as those previously coordinated by IPEM/BNMS. Ongoing audit of reporting within and between sites, and attendance at multidisciplinary meetings, is desirable. This includes compliance with the advice on revalidation on nuclear cardiology as set out by the Royal Colleges and appropriate Appropriate arrangements for consensus reporting between specialties should arranged locally when indicated, particularly when cardiac CT data is incorporated in the imaging investigation.
List of Abbreviations
Attenuation correction atrial fibrillation Administration of Radioactive Substances Advisory Committee computed tomography diastolic blood pressure left bundle branch block left posterior oblique right anterior oblique right bundle branch block systolic blood pressure single photon emission computed tomography ventricular fibrillation ventricular premature beat ventricular tachycardia 1 Brown KA, Heller GV, Landin RS, et al. Early dipyridamole (99m)Tc-sestamibi single photon emission computed tomographic imaging 2 to 4 days after acute myocardial infarction predicts in-
hospital and postdischarge cardiac events: comparison with submaximal exercise imaging.
Circulation 1999 Nov 16;100(20):2060-6.
2 Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery---executive summary a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update
the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).
Circulation 2002 Mar 12;105(10):1257-67.
3 Heller LI, Cates C, Popma J, et al. Intracoronary Doppler assessment of moderate coronary artery disease: comparison with 201Tl imaging and coronary angiography. FACTS Study Group.
Circulation 1997 Jul 15;96(2):484-90.
4 Zellweger MJ, Lewin HC, Lai S, et al. When to stress patients after coronary artery bypass surgery? Risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT:
implications of appropriate clinical strategies. J Am Coll Cardiol 2001 Jan;37(1):144-52.
5 Allman KC, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular
dysfunction: a meta-analysis. J Am Coll Cardiol 2002 Apr 3;39(7):1151-8.
6 Donaldson RM, Raphael M, Radley-Smith R, et al. Angiographic identification of primary coronary anomalies causing impaired myocardial perfusion. Cathet Cardiovasc Diagn 1983;9(3):237-49.
7 Lee YS, Moon DH, Shin JW, et al. Dipyridamole TI-201 SPECT imaging in patients with myocardial bridging. Clin Nucl Med 1999 Oct;24(10):759-64.
8 Fukuda T, Akagi T, Ishibashi M, et al. Noninvasive evaluation of myocardial ischemia in Kawasaki disease: comparison between dipyridamole stress thallium imaging and exercise stress testing. Am
Heart J
1998 Mar;135(3):482-7.
9 Miyagawa M, Mochizuki T, Murase K, et al. Prognostic value of dipyridamole-thallium myocardial scintigraphy in patients with Kawasaki disease. Circulation 1998 Sep 8;98(10):990-6.
10 Momose M, Babazono T, Kondo C, et al. Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of
haemodialysis. Eur J Nucl Med Mol Imaging 2009 Aug;36(8):1315-21.
11 O'Keefe JH, Jr., Bateman TM, Barnhart CS. Adenosine thallium-201 is superior to exercise thallium- 201 for detecting coronary artery disease in patients with left bundle branch block. J Am Coll Cardiol
1993 May;21(6):1332-8.
12 Muller-Suur R, Eriksson SV, Strandberg LE, et al. Comparison of adenosine and exercise stress test for quantitative perfusion imaging in patients on beta-blocker therapy. Cardiology 2001;95(2):112-8.
13 Jones I, Latus K, Bartle L, et al. Clinical competence in myocardial perfusion scintigraphic stress testing: general training guidelines and assessment. Nucl Med Commun 2007 Jul;28(7):575-82.
14 Rodgers GP, Ayanian JZ, Balady G, et al. American College of Cardiology/American Heart Association Clinical Competence Statement on Stress Testing. A Report of the American College of Cardiology/American Heart Association/American College of Physicians-American Society of
Internal Medicine Task Force on Clinical Competence. Circulation 2000 Oct 3;102(14):1726-38.
15 Department of Health. The ionising ratiation (medical exposure) regulations 2000. Department of Health publications 2011 November 1:1-13. Available from: URL: 16 Hill J, Timmis A. Exercise tolerance testing. BMJ 2002 May 4;324(7345):1084-7.
17 Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines).
Circulation 2002 Oct 1;106(14):1883-92.
18 Iskandrian AS, Heo J, Kong B, et al. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll
Cardiol
1989 Nov 15;14(6):1477-86.
19 Gupta NC, Esterbrooks DJ, Hilleman DE, et al. Comparison of adenosine and exercise thallium-201 single-photon emission computed tomography (SPECT) myocardial perfusion imaging. The GE
SPECT Multicenter Adenosine Study Group. J Am Coll Cardiol 1992 Feb;19(2):248-57.
20 Smits P, Lenders JW, Thien T. Caffeine and theophylline attenuate adenosine-induced vasodilation in humans. Clin Pharmacol Ther 1990 Oct;48(4):410-8.
21 Jacobson AF, Cerqueira MD, Raisys V, et al. Serum caffeine levels after 24 hours of caffeine abstention: observations on clinical patients undergoing myocardial perfusion imaging with
dipyridamole or adenosine. Eur J Nucl Med 1994 Jan;21(1):23-6.
22 Aqel RA, Zoghbi GJ, Trimm JR, et al. Effect of caffeine administered intravenously on intracoronary- administered adenosine-induced coronary hemodynamics in patients with coronary artery disease.
Am J Cardiol 2004 Feb 1;93(3):343-6.
23 Smits P, Corstens FH, Aengevaeren WR, et al. False-negative dipyridamole-thallium-201 myocardial imaging after caffeine infusion. J Nucl Med 1991 Aug;32(8):1538-41.
24 Zhao G, Messina E, Xu X, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor
agonist. J Cardiovasc Pharmacol 2007 Jun;49(6):369-75.
25 Reyes E, Stirrup J, Roughton M, et al. Attenuation of adenosine-induced myocardial perfusion heterogeneity by atenolol and other cardioselective beta-adrenoceptor blockers: a crossover
myocardial perfusion imaging study. J Nucl Med 2010 Jul;51(7):1036-43.
26 Shehata AR, Gillam LD, Mascitelli VA, et al. Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and
echocardiography. Am J Cardiol 1997 Aug 1;80(3):268-72.
27 Pennell DJ, Mavrogeni SI, Forbat SM, et al. Adenosine combined with dynamic exercise for myocardial perfusion imaging. J Am Coll Cardiol 1995 May;25(6):1300-9.
28 Reyes E, Loong CY, Wechalekar K, et al. Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease. J Nucl
Cardiol
2007 Nov;14(6):827-34.
29 Sundram F, Notghi A, Smith NB. Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma. Nucl Med Commun 2009 Mar;30(3):217-25.
Parker MW, Morales DC, Slim HB, et al. A strategy of symptom-limited exercise with regadenoson- as-needed for stress myocardial perfusion imaging: A randomized controlled trial. J Nucl Cardiol
2012 Nov; 28, ahead of print
Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter
international trial. J Nucl Cardiol 2007 Sep;14(5):645-58.
Cerqueira MD, Nguyen P, Staehr P, et al. Effects of Age, Gender, Obesity, and Diabetes on the
Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial
Perfusion Imaging: Integrated ADVANCE-MPI Trial Results. J Am Coll Cardiol Img 2008 May
1;1(3):307-16.
Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A
agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind,
placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008 May;15(3):319-28.
34 Leaker BR, O'Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a
randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008 May;15(3):329-36.
35 Cerqueira MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994 Feb;23(2):384-9.
36 Laarman GJ, Niemeyer MG, van der Wall EE, et al. Dipyridamole thallium testing: noncardiac side effects, cardiac effects, electrocardiographic changes and hemodynamic changes after dipyridamole
infusion with and without exercise. Int J Cardiol 1988 Aug;20(2):231-8.
37 Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 1990
Apr;81(4):1205-9.
38 Hays JT, Mahmarian JJ, Cochran AJ, et al. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator
pharmacologic stress testing. J Am Coll Cardiol 1993 Jun;21(7):1583-90.
39 Geleijnse ML, Elhendy A, Fioretti PM, et al. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000 Dec;36(7):2017-27.
40 Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation. British Cardiac Society Guidelines and Medical Practice Committee and
Royal College of Physicians Clinical Effectiveness and Evaluation Unit. Heart 2001 Feb;85(2):133-
42.
41 Reyes E, Loong CY, Harbinson M, et al. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol 2008 Dec 9;52(24):2008-16.
42 Coma-Canella I. Changes in plasma potassium during the dobutamine stress test. Int J Cardiol 1991 43 Wall BF, Meara JR, Muirhead CR. Protection of pregnant patients during diagnostic medical exposures to ionising radiation RCE 9. Health Protection Agency Publications 2009:1-16. Availablefrom: URL: 44 Yamamoto W, Shuke N, Usui K, et al. Intense uptake of technetium-99m tetrofosmin by lactating breasts. Clin Nucl Med 2001 Jan;26(1):76-7.
45 Dilsizian V, Rocco TP, Freedman NM, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990 Jul
19;323(3):141-6.
46 van Eck-Smit BL, van der Wall EE, Zwinderman AH, et al. Clinical value of immediate thallium-201 reinjection imaging for the detection of ischaemic heart disease. Eur Heart J 1995 Mar;16(3):410-20.
47 Administration of Radioactive Substance Advisory Committee. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources: Diagnosticprocedures, adult patients. ARSAC 2006;33-7.
48 Rocco TP, Dilsizian V, McKusick KA, et al. Comparison of thallium redistribution with rest "reinjection" imaging for the detection of viable myocardium. Am J Cardiol 1990 Jul 15;66(2):158-63.
49 Maurea S, Cuocolo A, Soricelli A, et al. Enhanced detection of viable myocardium by technetium- 99m-MIBI imaging after nitrate administration in chronic coronary artery disease. J Nucl Med 1995
Nov;36(11):1945-52.
50 Thorley PJ, Bloomer TN, Sheard KL, et al. The use of GTN to improve the detection of ischaemic myocardium using 99Tcm-tetrofosmin. Nucl Med Commun 1996 Aug;17(8):669-74.
51 van Dongen AJ, van Rijk PP. Minimizing liver, bowel, and gastric activity in myocardial perfusion SPECT. J Nucl Med 2000 Aug;41(8):1315-7.
52 Hurwitz GA, Clark EM, Slomka PJ, et al. Investigation of measures to reduce interfering abdominal activity on rest myocardial images with Tc-99m sestamibi. Clin Nucl Med 1993 Sep;18(9):735-41.
53 Cherng SC, Chen YH, Lee MS, et al. Acceleration of hepatobiliary excretion by lemon juice on 99mTc-tetrofosmin cardiac SPECT. Nucl Med Commun 2006 Nov;27(11):859-64.
54 Beange I, Bhatia B, Shakeshaft J, et al. IPEM Report 99. Institute of Physics and Engineering in Medicine; 2010.
55 Busemann SE, Plachcinska A, Britten A, et al. Routine quality control recommendations for nuclear medicine instrumentation. Eur J Nucl Med Mol Imaging 2010 Mar;37(3):662-71.
56 Institute of Physics and Engineering in Medicine. Recommended standards for the routine performance testing of diagnostic X ray imaging systems; IPEM Report 91. 2005.
57 Nishina H, Slomka PJ, Abidov A, et al. Combined supine and prone quantitative myocardial perfusion SPECT: method development and clinical validation in patients with no known coronary
artery disease. J Nucl Med 2006 Jan;47(1):51-8.
58 Strauss HW, Miller D, Wittry MD, et al. Procedure guideline for myocardial perfusion imaging 3.3.
Society of Nuclear Medicine Procedure Guidelines 2008Available from: URL:DOI:10.2967/jnmt.108.056465 59 Holly T, Abbott BG, Al-Mallah M, et al. Single photon-emission computed tomography. ASNC imaging guidelines for nuclear cardiology procedures 2010Available from: URL:DOI:10.1007/s12350-010-9246-y 60 Germano G, Kiat H, Kavanagh PB, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995 Nov;36(11):2138-47.
61 Thompson RC, Heller GV, Johnson LL, et al. Value of attenuation correction on ECG-gated SPECT myocardial perfusion imaging related to body mass index. J Nucl Cardiol 2005 Mar;12(2):195-202.
62 Baghdasarian SB, Noble GL, Ahlberg AW, et al. Risk stratification with attenuation corrected stress Tc-99m sestamibi SPECT myocardial perfusion imaging in the absence of ECG-gating due to
arrhythmias. J Nucl Cardiol 2009 Jul;16(4):533-9.
63 Links JM, DePuey EG, Taillefer R, et al. Attenuation correction and gating synergistically improve the diagnostic accuracy of myocardial perfusion SPECT. J Nucl Cardiol 2002 Mar;9(2):183-7.
64 Candell-Riera J, Santana-Boado C, Bermejo B, et al. Interhospital observer agreement in interpretation of exercise myocardial Tc-99m tetrofosmin SPECT studies. J Nucl Cardiol 2001
Jan;8(1):49-57.
65 DePuey EG, III. How to detect and avoid myocardial perfusion SPECT artifacts. J Nucl Med 1994 66 Iskandrian AS, Heo J, Nguyen T, et al. Left ventricular dilatation and pulmonary thallium uptake after single-photon emission computer tomography using thallium-201 during adenosine-induced
coronary hyperemia. Am J Cardiol 1990 Oct 1;66(10):807-11.
67 Winzelberg GG. Right ventricular visualization --thallium 201 cardiac imaging. Semin Nucl Med 1982 68 Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from
the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart
Association. Circulation 2002 Jan 29;105(4):539-42.
69 Sabharwal N, Loong CY, Kelion A. Myocardial perfusion scintigraphy: image interpretation. Nuclear cardiology. First ed. Oxford: Oxford University Press, 2008. p. 121-70.
70 Mahmarian JJ, Boyce TM, Goldberg RK, et al. Quantitative exercise thallium-201 single photon emission computed tomography for the enhanced diagnosis of ischemic heart disease. J Am Coll
Cardiol
1990 Feb;15(2):318-29.
71 Weiss AT, Maddahi J, Lew AS, et al. Reverse redistribution of thallium-201: a sign of nontransmural myocardial infarction with patency of the infarct-related coronary artery. J Am Coll Cardiol 1986
Jan;7(1):61-7.
72 Araujo W, DePuey EG, Kamran M, et al. Artifactual reverse distribution pattern in myocardial perfusion SPECT with technetium-99m sestamibi. J Nucl Cardiol 2000 Nov;7(6):633-8.
73 Abidov A, Hachamovitch R, Hayes SW, et al. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion
study. Circulation 2003 Jun 17;107(23):2894-9.
74 Mathur S, Shah AR, Ahlberg AW, et al. Blunted heart rate response as a predictor of cardiac death in patients undergoing vasodilator stress technetium-99m sestamibi gated SPECT myocardial
perfusion imaging. J Nucl Cardiol 2010 Aug;17(4):617-24.
75 Hachamovitch R, Berman DS, Shaw LJ, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: differential
stratification for risk of cardiac death and myocardial infarction. Circulation 1998 Feb 17;97(6):535-
43.
76 Hitzel A, Manrique A, Cribier A, et al. Diagnostic value of Tl-201 lung uptake is dependent on measurement method. J Nucl Cardiol 2001 May;8(3):332-8.

Source: http://www.bncs.org.uk/resources/3F9_MPS_procedure_guidelines_Final_12.pdf

headtotoehealthcare.org

Bleaching products fade areas of unwanted pigmentation by disrupting the production and distribution of melanin in the skin by targeting overactive melanocytes (pigment-producing cells). There are a variety of ways to accomplish this and studies have shown that the best results occur when using a combination of two or more of these ingredients. Tyrosinase Inhibitors: Tyrosinase is a copper enzyme which stimulates melanin production in the melanocyte. Most whitening agents fall under this category, interfering with the enzymes function and reducing pigment production in the melanocyte. Hydroquinone Hydroquinone is a hydroxyphenolic compound that has been widely used for skin lightening for 50 years. It is the only FDA approved product for bleaching and a prescription is required to obtain products with a concentration above 2%. It is the most widely studied and scientifically backed bleaching agent on the market, but its use can come at a cost. It can be very irritating to sensitive skin and cause pigmentation to darken and get worse. In very dark skin types, long term use of highly concentrated products (4% or more) can lead to a development of Exogenous Ochronosis, "an irreversible disfiguring cosmetic problem." It is also very difficult to stabilize and can oxidize quickly if exposed to light and air. If a product containing Hydroquinone has darkened from an off-white or a creamy, pale yellow to a gold or brown color, it will no longer be effective and should be discarded. When using Hydroquinone, it is imperative to stay out of the sun for the treatment to work. Always wear a full spectrum sunblock and a hat. Exposure to sun deteriorates the Hydroquinone, rendering it ineffective. Kojic Acid Kojic Acid, a byproduct of the fermentation of rice, was first discovered in Japan in 1907. Kojic acid is the most common bleaching agent next to Hydroquinone. Kojic Acid is a natural and more gentle on the skin alternative to using Hydroquinone. It penetrates the upper skin layers and inhibits the production of epidermal melanin. Kojic Acid does pose a risk of causing allergic or sensitizing reactions in a small number of people. Azelaic Acid A natural skin brightener found in wheat, rye, and barley. Azelaic acid is most effective in concentrations of 20% - an amount that makes is near comparable in activity to 4% Hydroquinone. In a study consisting of 329 melasma sufferers, half were treated with a 20% Azelaic Acid solution, and half were treated with a 4% Hydroquinone solution. 56% of patients treated with AZA had good to favorable results while 73% treated with HQ had a similar result. When combined with Tretinoin or Alpha Hydroxy Acids, the results were noticeably improved. Azelaic Acid, is also antibacterial and anti-inflammatory, so it is also effective in the treatment of rosacea and acne. Arbutin (also known as Alpha Arbutin, Bearberry Extract or Uva Ursi Extract) A botanical, naturally-occuring cousin to Hydroquinone, Arbutin was first discovered in the Uva Ursi plant. Compared to HQ, Arbutin has been shown to be significantly less cytotoxic to the melanocyte — making it a much safer, yet very effective alternative to Hydroquinone. In a clinical trial involving Japanese women with melasma, a 3% concentration of Arbutin produced good to excellent results in 71.4% of patients within a three month period. Licorice Extract One of the safest and most gentle bleaching agents around, Licorice Extract is a potent anti-inflammatory and antioxidant. The ingredients responsible for the skin whitening aspect of the plan are known as Glabradin and Liquiritin. Liquiritin (in a 20% concentration) has been shown to provide good to excellent results in 70-90% of patients with hyperpigmentation and melasma — with minimal side effects and only minor irritation. Mulberry Extract Mulberry Extract is derived from the root bark of the mulberry tree, Morus Alba L. Studies have confirmed it to effectively reduce tyrosinase activity at much lower concentrations than either Hydroquinone or Kojic Acid. N-Acetyl Glucosamine N-Acetyl Glucosamine is a more stable form of Glucosamine, an agent most widely known as an arthritis treatment. Studies have recently shown it to successfully reduce the amount of melanin in melanocytes by blocking tyrosinase conversion and its results improve significantly when combined with Niacinamide. Inhibition of Melanosome Transfer: These skin lightening agents lighten unwanted pigmentation by interfering with the transfer or melanosomes from the melanocyte to the keratinocytes. Niacinamide or Nicotinamide is a biologically active form of Niacin (Vitamin B3) that has been shown to interrupt melanocyte transfer by 35-68%.

15-daagse rondreis israël

15-tägige Rundreise nach Jordanien 19. Mai - 2. Juni 2014 3 Meere – 3 Wüsten – 3 Städte. Höhepunkte: 7 Offenbarungsberge Gottes – Tiefstpunkt der Erde: Das Tote Meer Israel, das Land in dem Gott Geschichte gemacht hat. Wir besuchen berühmte Städte wie Tel